Neurosarcoidosis and infliximab therapy monitored by 18FDG PET/CT

QJM. 2019 Sep 1;112(9):695-697. doi: 10.1093/qjmed/hcz148.

Authors

E Rivière^{1

2}, P Schwartz³, I Machelart¹, C Greib¹, J-L Pellegrin^{1

4}, J-F Viallard^{1

2}, E Lazaro^{1

4}

Affiliations

¹ Department of Internal Medicine and Infectious Diseases, Haut-Leveque Hospital, University Hospital of Bordeaux, Pessac, France.
² INSERM U1034, University of Bordeaux, Pessac, France.
³ Nuclear Medicine Department, Haut-Leveque Hospital, University Hospital of Bordeaux, Pessac, France.
⁴ CIRID, UMR/CNRS 5164, University of Bordeaux, Bordeaux, France.

PMID: 31225618
DOI: 10.1093/qjmed/hcz148

No abstract available

Publication types

Case Reports

MeSH terms

Anti-Inflammatory Agents / therapeutic use*
Central Nervous System Diseases / diagnostic imaging
Central Nervous System Diseases / drug therapy*
Central Nervous System Diseases / physiopathology
Fluorodeoxyglucose F18 / administration & dosage
Humans
Infliximab / therapeutic use*
Male
Middle Aged
Positron Emission Tomography Computed Tomography*
Radiopharmaceuticals / administration & dosage
Sarcoidosis / diagnostic imaging
Sarcoidosis / drug therapy*
Sarcoidosis / physiopathology
Treatment Outcome

Substances

Anti-Inflammatory Agents
Radiopharmaceuticals
Fluorodeoxyglucose F18
Infliximab

Supplementary concepts

Neurosarcoidosis